Last reviewed · How we verify
Vaginal dinoprostone
At a glance
| Generic name | Vaginal dinoprostone |
|---|---|
| Also known as | Dinoprostone vaginal insert, Controlled-release dinoprostone delivery system, Vaginal prostaglandin E2 |
| Sponsor | Hospital Universitario 12 de Octubre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PGE2 Followed by Oxytocin vs Oxytocin in Term PROM (POXY-PROM) (NA)
- Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies (PHASE3)
- Mechanical Dilation of the Cervix in a Scarred Uterus (NA)
- Early V/S Delayed Induction of Labour in Patients With Prelabour Rupture of Membranes (NA)
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter (PHASE4)
- Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess (PHASE3)
- Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal dinoprostone CI brief — competitive landscape report
- Vaginal dinoprostone updates RSS · CI watch RSS
- Hospital Universitario 12 de Octubre portfolio CI